Aspira Women’s Health (NASDAQ:AWH) PT Lowered to $5.50

Aspira Women’s Health (NASDAQ:AWH) had its price target decreased by Alliance Global Partners from $7.00 to $5.50 in a research note issued to investors on Wednesday, MarketBeat.com reports. Alliance Global Partners currently has a buy rating on the stock.

Separately, StockNews.com raised Aspira Women’s Health from a sell rating to a hold rating in a research note on Wednesday.

Aspira Women’s Health Stock Down 3.6 %

AWH stock opened at $1.06 on Wednesday. The business has a fifty day moving average of $1.39 and a two-hundred day moving average of $2.74. The stock has a market cap of $17.02 million, a price-to-earnings ratio of -0.73 and a beta of 1.54. Aspira Women’s Health has a 52-week low of $0.86 and a 52-week high of $6.75.

Aspira Women’s Health (NASDAQ:AWH) last posted its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million for the quarter, compared to analyst estimates of $2.60 million. During the same period last year, the business earned ($0.28) EPS. As a group, sell-side analysts anticipate that Aspira Women’s Health will post -1.29 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its stake in Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 179,371 shares of the company’s stock after purchasing an additional 53,997 shares during the period. B. Riley Wealth Advisors Inc. owned about 1.73% of Aspira Women’s Health worth $732,000 at the end of the most recent quarter. 12.19% of the stock is owned by institutional investors and hedge funds.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.